This protocol outlines a randomized, double-blind, multicenter trial that directly compares two reversal regimens for neuromuscular blockade following limited thoracoscopic lung resection. The study team will randomize patients to receive either sugammadex at 2 mg/kg or neostigmine at 0.03 mg/kg co-administered with atropine 0.015 mg/kg. The intervention is explicitly described in the abstract; dosing and co-administration details were reported by the authors.
The authors designed the comparison to test whether an optimized reversal strategy with sugammadex improves early postoperative respiratory mechanics relative to routine neostigmine reversal. The trial is double-blind and multicenter, and the protocol specifies a 1:1 randomization scheme. The trial is registered on ClinicalTrials.gov (NCT07309393), as noted in the abstract.
Investigators selected percentage decrease in forced expiratory volume in 1 second (FEV1) at 1 hour after surgery, relative to the patient’s preoperative baseline, as the primary outcome. This choice reflects the research team’s focus on immediate postoperative pulmonary function following thoracic surgery, a period when respiratory performance commonly worsens and is often underappreciated.
The primary endpoint is physiologic and quantitative. The protocol does not provide additional measurement timing specifics, such as the number of spirometric attempts, criteria for acceptable effort, or whether incentives or coached maneuvers will be used; those methodological details were not reported in the abstract.
Secondary endpoints include the percentage decrease in FEV1 from baseline on postoperative days 1 through 3. The authors will also record pain scores using the verbal response scale (VRS) at multiple postoperative time points. Other planned outcomes are opioid consumption, recovery time of gastrointestinal function, incidence of postoperative nausea and vomiting (PONV), the 15-item Quality of Recovery (QoR-15) scores, and the incidence of postoperative pulmonary complications (PPCs).
Those measures combine objective physiologic data, analgesic utilization metrics, and patient-reported recovery indices. The protocol abstract lists these outcomes, but it did not report the schedule of assessments for every secondary endpoint, nor did it present prespecified thresholds for PPCs or definitions used for gastrointestinal recovery; such protocol-level details were not included in the abstract.
The study will enroll 240 patients undergoing unilateral thoracoscopic partial lung resection of one segment or less. Patients will be randomly assigned in equal proportions to the two reversal strategies. The trial is labeled as multicenter and double-blind in the abstract, indicating that both patients and outcome assessors (and presumably clinicians administering the reversal drugs) will be masked to allocation.
Doses are reported: sugammadex 2 mg/kg; neostigmine 0.03 mg/kg plus atropine 0.015 mg/kg. The authors did not report, in the abstract, whether neuromuscular monitoring thresholds (such as train-of-four ratios) will guide the timing of reversal administration or extubation criteria. Those monitoring and intraoperative management specifics were not present in the abstract.
The protocol frames residual neuromuscular blockade (RNMB) as a controllable risk factor that may contribute to the immediate postoperative decline in pulmonary function after thoracic operations. The study aims to determine whether reversing neuromuscular blockade with sugammadex—a selective relaxant-binding agent—produces superior recovery of early respiratory mechanics compared with cholinesterase inhibition with neostigmine.
This mechanistic focus responds to a clinical gap: pulmonary function commonly drops after thoracic surgery and few targeted interventions address that early decline. The authors argue that if optimized reversal reduces early respiratory impairment, that would support further trials designed around patient-centered outcomes.
The abstract does not provide several protocol elements readers often seek. It did not report specific inclusion and exclusion criteria beyond the surgical procedure, did not describe anesthetic or ventilatory management standards, and did not state whether objective neuromuscular monitoring will determine the timing of reversal or extubation. The expected effect size, power calculation, or planned statistical methods were not presented in the abstract. Interim analyses and stopping rules were also not mentioned.
Those missing details limit the ability to fully appraise the protocol from the abstract alone. The authors noted that the findings will supply mechanistic evidence and may inform the design of future confirmatory trials with patient-centered outcomes, implying that this trial is powered and scoped to test physiologic superiority rather than definitive patient-centered endpoints.
Limitations that remain open based on the abstract: whether neuromuscular monitoring will standardize RNMB assessment; whether definitions for PPCs and gastrointestinal recovery will be harmonized across centers; and what magnitude of FEV1 improvement the investigators consider clinically meaningful. These unanswered questions will matter for interpreting the eventual results and for designing subsequent confirmatory studies.